Manufacturing Innovation Centre, Braintree, UK

The CGT Catapult Manufacturing Innovation Centre, due to become fully operational by December 2021, is being developed following a £100m commitment by the Government to

  • support the national effort to manufacture millions of doses of COVID-19 vaccine
  • become an innovation centre for cell and gene therapies supporting the growth of this expanding industry
  • continue to promote innovation and develop technology transfer expertise for vaccines and large-scale cell and gene therapy manufacture
     
 

COVID-19 vaccine response

Responding to the coordinated national effort backed by the UK Government led by the appointed Vaccine Taskforce, we are establishing the CGT Catapult Manufacturing Innovation Centre as a flexible facility to support the national and international response to the COVID-19 pandemic. We are installing state-of-the-art equipment, including up to 1,000L bioreactors, and providing our expertise to prepare the facility in Braintree for manufacturing millions of doses of vaccine per month.

The centre is scheduled to become fully operational by December 2021 when it is forecast that COVID-19 vaccine candidates will be approved for use.

The centre complements the Vaccines Manufacturing and Innovation Centre (VMIC) currently being built in Oxfordshire. It is important to have multiple facilities to build the manufacturing resilience needed to ensure the UK has long-term capacity to meet future pandemics.

 

Centre for innovation and technology transfer expertise 

We are engaging with the whole industry, CDMOs and developers to determine the best way of supporting continued growth of the UK cell and gene therapy industry moving forward.

The CGT Catapult Manufacturing Innovation Centre will become a state-of-the-art facility, developing expertise and driving innovation into technology transfer for novel therapies and vaccines manufacturing at industrial scale. Large-scale gene therapy manufacturing systems will also be developed at the facility as we aim to fulfil the immediate and long-term needs of the UK cell and gene therapy industry.

 

Discover who we are